Mesothelioma is a rare type of cancer, most often caused by exposure to asbestos, according to the U.S. Centers for Disease ...
By: Graham Tse, M.D., chief medical officer, Miller Children’s & Women’s Hospital When your child needs medical care—whether it’s a routine checkup, help managing a chronic condition, or support ...
As of Friday, January 23, Apogee Therapeutics, Inc.’s APGE share price has dipped by 8.67%, which has investors questioning ...
Omalizumab or dupilumab suggested for adults with moderate-to-severe allergic asthma, history of exacerbations requiring oral corticosteroids ...
Five years after her middle son was diagnosed with the chronic lung condition, country singer Jessie James Decker has learned ...
More than 140 U.S. medical organizations are advocating for the passage of a bill that would increase NIH funding for fiscal ...
A woman has praised an urgent treatment centre (UTC) after it discovered she had a heart condition. Staff at the Corby UTC in ...
Asthma is one of the most prevalent chronic inflammatory respiratory diseases across the globe, with a significant increase ...
A new study shows that internet-delivered cognitive behavioral therapy (ICBT) can effectively reduce asthma-related anxiety ...
Spiro Medical, which debuted last year, reeled in $67 million in series A funding it plans to use to develop its novel treatment for asthma.
The SWIFT-1 and -2 phase 3 trials demonstrated "significantly" lower rate of annualized asthma exacerbations in patients receiving twice-yearly depemokimab vs placebo. The FDA approved ...
Depemokimab (brand name Exdensur) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and is the first and only ultra-long-acting biologic with twice-yearly dosing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results